UPSC has extended the NDA & CDS I 2025 registration deadline to 6 PM on 1 January 2025 due to technical issues. Candidates ...

Sentynl took over the therapy’s development and commercialisation from Fortress Biotech's subsidiary Cyprium Therapeutics.

The Union Public Service Commission (UPSC) has extended the registration deadline for the NDA & CDS I 2025 exams until ...

The article below provides detailed information about the NDA and CDS online application process, which includes application fees and other important information. Candidates who want to join the ...

The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...

LOS ALTOS, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: UNCY), a clinical-stage biotechnology company developing ...

UPSC NDA & NA I Exam 2025 registration closes today, December 31. Eligible candidates can apply online and make corrections ...

Fortress Biotech (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics announced the acceptance for review of the New Drug Application ...

The NDA is supported by data from the open-label, single-center phase 1/2 90-CH-0149 trial and the open-label, single-arm phase 3 09-CH-0059 study.

Union Public Service Commission has extended the UPSC NDA & CDS I 2025 registration date. Candidates who want to apply for ...